.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 3,966,962

« Back to Dashboard

Claims for Patent: 3,966,962

Title: Triacetin solutions of PGE-type compounds
Abstract:A stable dosage form of PGE-type compounds is obtained by dissolving these compounds in triacetin.
Inventor(s): Yalkowsky; Samuel H. (Portage, MI)
Assignee: The Upjohn Company (Kalamazoo, MI)
Application Number:05/562,535
Patent Claims: 1. A stable dosage form of a prostaglandin-like compound of the PGE-type comprising a solution of said compound in triacetin.

2. A stable dosage form according to claim 1 wherein said solution contains said compound in a concentration range 0.1 to 10 mg. per ml. of triacetin.

3. A stable dosage form according to claim 1 wherein said solution is contained in a capsule of a pharmaceutically acceptable water-dispersable material.

4. A stable dosage form according to claim 3 wherein said material contains gelatin and the capsule is soft and elastic.

5. A stable dosage form according to claim 1 wherein said compound is PGE.sub.2, PGE.sub.2 methyl ester, 16,16-dimethyl-PGE.sub.2, 16,16-dimethyl-PGE.sub.2 methyl ester, 15-methyl-PGE.sub.2, 15-methyl-PGE.sub.2 methyl ester, 15(R)-15-methyl-PGE.sub.2, or 15(R)-15-methyl-PGE.sub.2 methyl ester.

6. A stable dosage form according to claim 5 wherein the triacetin solution is contained in a soft elastic gelatin capsule, and said compound is present in a concentration range 0.1 to 10 mg. per ml. of triacetin.

7. A stable dosage form according to claim 4 wherein the compound is 16,16-dimethyl-PGE.sub.2 or 16,16-dimethyl-PGE.sub.2 methyl ester, and said compound is present in a concentration range 0.5 to 5 mg. per ml. of triacetin.

8. A stable dosage form according to claim 4 wherein the compound is 15-methyl-PGE.sub.2 or 15-methyl-PGE.sub.2 methyl ester, and said compound is present in a concentration range 0.5 to 5 mg. per ml. of triacetin.

9. A stable dosage form according to claim 4 wherein the compound is 15(R)-15-methyl-PGE.sub.2 or 15(R)-15-methyl-PGE.sub.2 methyl ester, and said compound is present in a concentration range 0.5 to 5 mg. per ml. of triacetin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc